BDBM356271 US10604535, Example 169::US11584758, Compound I-1::US9815850, Compound 169::US9815850, Compound 42::US9896458, No. 169

SMILES CN1c2ncccc2OC[C@H](NC(=O)c2nnc(Cc3ccccc3)[nH]2)C1=O

InChI Key

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 356271   

TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM356271(US10604535, Example 169 | US11584758, Compound I-1...)
Affinity DataIC50:  500nMAssay Description:Test compounds were diluted in DMSO and 0.1 μL of solution was dispensed to each well of a 384-well white solid microplate. The assay buffer was...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM356271(US10604535, Example 169 | US11584758, Compound I-1...)
Affinity DataIC50:  500nMAssay Description:Test compounds were diluted in DMSO and 0.1 μL of solution was dispensed to each well of a 384-well white solid microplate. The assay buffer was...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM356271(US10604535, Example 169 | US11584758, Compound I-1...)
Affinity DataIC50:  500nMAssay Description:Assay was performed in polystyrene low volume 384-well black plate, at Room Temperature (RT) in a final volume of 10.1 μl/well using 10 nM of GS...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM356271(US10604535, Example 169 | US11584758, Compound I-1...)
Affinity DataIC50:  37.5nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo™ technology. ADP-Glo™ (Promega, Madison, Wis....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM356271(US10604535, Example 169 | US11584758, Compound I-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Fluorescent polarization binding assay was performed in polystyrene low volume 384-well black plate, at Room Temperature (RT) in a final volume of 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM356271(US10604535, Example 169 | US11584758, Compound I-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Fluorescent polarization binding assay was performed in polystyrene low volume 384-well black plate, at Room Temperature (RT) in a final volume of 10...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM356271(US10604535, Example 169 | US11584758, Compound I-1...)
Affinity DataIC50:  500nMAssay Description:Assay was performed in polystyrene low volume 384-well black plate, at Room Temperature (RT) in a final volume of 10.1 μl/well using 10 nM of GS...More data for this Ligand-Target Pair
In DepthDetails US Patent